New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
09:13 EDTONCYOncolytics Biotech reports FY12 EPS (C$0.48), consensus (43c)
Reports FY12 Research and development expensed C$31.4M.
News For ONCY From The Last 14 Days
Check below for free stories on ONCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
06:49 EDTONCYOncolytics Biotech reports evaluation of clinical study with REOLYSIN
Oncolytics Biotech announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Researchers examined REOLYSIN in panels of both normal and malignant liver cells and administered either REOLYSIN or saline to SCID mice with HCV-positive HCC xenografts. The aims of the study were to assess interferon secretion in normal and malignant liver cells in response to reovirus infection; the effects of reovirus infection in normal and malignant liver cells on HBV and HCV proteins; and the anti-viral and anti-cancer effects of reovirus in vivo. Based on these results, the investigators are evaluating the conduct of a translation clinical study.
06:47 EDTONCYOncolytics Biotech collaborators present preclinical research on liver cancer
Oncolytics Biotech announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Researchers examined Reolysin in panels of both normal and malignant liver cells and administered either Reolysin or saline to SCID mice with HCV-positive HCC xenografts. The aims of the study were to assess interferon secretion in normal and malignant liver cells in response to reovirus infection; the effects of reovirus infection in normal and malignant liver cells on HBV and HCV proteins; and the anti-viral and anti-cancer effects of reovirus in vivo. The study results showed that reovirus infection of primary human liver cells and HCC lines induced a robust type I interferon response; that reovirus-conditioned media from both primary human liver cells and JHH1 cells potently inhibits HCV and HBV in vitro with these effects abrogated by the blockade of the type I interferon receptor and soluble interferon beta; and that reovirus inhibits HCC xenograft growth and HCV replication in vivo. The researchers concluded that the results described a novel dual anti-viral and anti-cancer mechanism for reovirus in HBV/HCV-positive HCC and that reovirus treatment of patients with HBV/HCV positive HCC will likely lead to the suppression, rather than exacerbation, of the underlying oncogenic viral infection. Based on these results, the investigators are evaluating the conduct of a translation clinical study.
06:33 EDTONCYOncolytics Biotech collaborators present head, neck cancer biomarker poster
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use